Results 21 to 30 of about 4,259,087 (330)

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

open access: yesCancers, 2021
Simple Summary Beyond mutations, epigenetic changes have been described as drivers for cancer as well. While leaving the overall DNA structure intact, they can be responsible for tumor malignancy by mediating the transcriptional upregulation of oncogenes.
Robert Jenke   +4 more
semanticscholar   +1 more source

HDAC Inhibitors: Innovative Strategies for Their Design and Applications

open access: yesMolecules, 2022
Histone deacetylases (HDACs) are a large family of epigenetic metalloenzymes that are involved in gene transcription and regulation, cell proliferation, differentiation, migration, and death, as well as angiogenesis.
Mateusz Daśko   +3 more
semanticscholar   +1 more source

HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity

open access: yesCancers, 2021
Simple Summary Tumor heterogeneity promotes the development of drug resistance in cancer. HDAC inhibitors modulate several processes that contribute to intra-tumoral heterogeneity. With careful consideration of the underlying biology, HDAC inhibitors can
Dimitris Karagiannis, T. Rampias
semanticscholar   +1 more source

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer

open access: yesCancer Drug Resistance, 2022
Epigenetic mechanisms play an important role in the development and persistence of cancer, and histone deacetylase (HDAC) inhibitors are promising anticancer drugs targeting epigenetic modes.
B. Biersack, B. Nitzsche, M. Höpfner
semanticscholar   +1 more source

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells

open access: yesFrontiers in Oncology, 2021
We have extended our analyses of HDAC inhibitor biology in sarcoma. The multi-kinase inhibitor axitinib interacted with multiple HDAC inhibitors to kill sarcoma cells.
Jane L. Roberts   +3 more
doaj   +1 more source

HDAC-Specific Inhibitors Induce the Release of Porcine Epidemic Diarrhea Virus via the COPII-Coated Vesicles

open access: yesViruses, 2023
Porcine epidemic diarrhea virus (PEDV) is an alpha-coronavirus causing acute diarrhea and high mortality in neonatal suckling piglets, resulting in huge economic losses for the global swine industry.
Ying Yang   +5 more
doaj   +1 more source

Discovery of 1-benzhydryl piperazine-based HDAC inhibitors with anti-cancer and anti-metastatic properties against human breast cancer: synthesis, molecular modeling, in vitro and in vivo biological evaluation [PDF]

open access: yes, 2022
Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors.
Milos , Petkovic   +11 more
core   +2 more sources

Nɛ-acetyl lysine derivatives with zinc binding groups as novel HDAC inhibitors [PDF]

open access: yesRoyal Society Open Science, 2019
HDAC inhibitors have been developed very rapidly in clinical trials and even in approvals for treating several cancers. However, there are few reported HDAC inhibitors designed from Nɛ-acetyl lysine.
Fang Wang   +9 more
doaj   +1 more source

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model [PDF]

open access: yes, 2011
NOTICE: this is the author’s version of a work that was accepted for publication in Neurobiology of Disease. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control ...
Ezzatizadeh, V   +17 more
core   +1 more source

Design, synthesis, molecular docking study, and biological evaluation of salicylaldimine derivatives as potential histone deacetylases inhibitors (HDACi) and anticancer agents

open access: yesArchives of Pharmaceutical Sciences Ain Shams University, 2018
Despite the increased success rates of histone deacetylases inhibitors (HDACi) as potent anticancer agents, many metabolic obstacles face the hydroxamic acid-based HDAC inhibitors, which inspired us to develop non-hydroxamate HDAC inhibitors.
Heba M. Hesham   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy